4 th October is a brilliant day for me as my first grandchild, a lovely princess, has made her grand appearance.
Covid 19 has caught up with President Donald Trump, the most powerful man on the planet.
The obvious reason for the infection has to be throwing caution to the winds by him, albeit for political impact.
Getting tested multiple times in a day does NOT prevent getting infected if one does not follow simple rules of maintaining safe distance, wearing a mask in a crowd and frequent washing hands.
But we must pray that he not only recovers fast , but also bounces back fully.
The little Princess wishes Mr. Donald Trump the best of health and loads of good luck.
He has an election to fight.
I anticipate good recovery despite his age and weight because he has been administered 8 grams of a combination of monoclonal antibodies while still in the White House. Monoclonal antibodies are synthetic antibodies that hasten recovery and reduce virus load.
Mr. Trump has also received 2 doses of Remdesivir , an anti viral that has been shown in randomized trials to significantly cut down recovery time and show a trend to reduced mortality. He should get a 5 days course.
Mr Trump is on an H2 blocker called famotidine , which has been shown to reduce need for intubation and mortality in moderately sick Covid patients. Famotidine is freely available in India, it is supposed to prevent an imminent cytokine storm, being a histamine blocker.
He is also being given vitamin D that observational studies have shown reduces morbidity and mortality when present in sufficient levels.
References:-
Dual-histamine receptor blockade with cetirizine – famotidine reduces pulmonary symptoms in COVID-19 patients
Pulmonary Pharmacology & Therapeutics
Remdesivir for the Treatment of Covid-19 — Preliminary Report
This article was published on May 22, 2020, at NEJM.org.
DOI: 10.1056/NEJMoa2007764
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Lancet 2020; 395: 1569–78
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
This article was published on May 27, 2020, at NEJM.org.
DOI: 10.1056/NEJMoa2015301
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 A Randomized Clinical Trial
JAMA. doi:10.1001/jama.2020.16349 Published online August 21, 2020.
Vitamin D sufficiency, a serum 25- hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection
PLoS ONE 15(9): e0239799. 10.1371/journal.pone.0239799
Evidence Supports a Causal Role for Vitamin D Status in Global COVID-19
Outcomes
medRxiv preprint doi:
Vitamin D insufficiency is prevalent in severe COVID-19
medRxiv preprint doi:
Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data
cite this as: BMJ 2017;356:i6583
New York clinical trial quietly tests heartburn remedy against coronavirus By Brendan Borrell Apr. 26, 2020 , Science.
When it comes to experience with COVID-19, he says, “No amount of smart people at the [National Institutes of Health] or Harvard or Stanford can outclass an average doctor in Wuhan.”
Early data shows promising results from Regeneron’s antibody cocktail for coronavirus
By Jen Christensen, CNN
September 30, 2020 CNN Health
Regeneron’s experimental on a virus antibody cocktail which is being used to treat President Trump saw success in early tests, driving down viral loads
and cutting recovery times in HALF
By NATALIE RAHHAL US HEALTH EDITOR
PUBLISHED: 22:38 BST, 2 October 2020 | UPDATED: 03:35 BST, 3 October 2020
Daily Mail.
